Can Large Simple Trials Help Us Understand When and How to Use Generic Drugs for Uncommon Diseases?

REFERENCES

1. 1.↵
   1. Tashkin DP,
   2. Elashoff R,
   3. Clements PJ,
   4. Goldin J,
   5. Roth MD,
   6. Furst DE,
   7. et al.

   Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Tashkin DP,
   2. Elashoff R,
   3. Clements PJ,
   4. Roth MD,
   5. Furst DE,
   6. Silver RM,
   7. et al.

   Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026–34.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Hoyles RK,
   2. Ellis RW,
   3. Wellsbury J,
   4. Lees B,
   5. Newlands P,
   6. Goh NS,
   7. et al.

   A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962–70.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Fischer A,
   2. Brown K,
   3. du Bois RM,
   4. Frankel SK,
   5. Cosgrove GP,
   6. Fernandez-Perez ER,
   7. et al.

   Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40:640–6.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Swigris JJ,
   2. Olson AL,
   3. Fischer A,
   4. Lynch DA,
   5. Cosgrove GP,
   6. Frankel SK,
   7. et al.

   Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130:30–6.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Liossis SN,
   2. Bounas A,
   3. Andonopoulos AP

   . Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45:1005–8.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Zamora AC,
   2. Wolters PJ,
   3. Collard HR,
   4. Connolly MK,
   5. Elicker BM,
   6. Webb WR,
   7. et al.

   Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102:150–5.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Gerbino AJ,
   2. Goss CH,
   3. Molitor JA

   . Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455–60.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Saketkoo LA,
   2. Espinoza LR

   . Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 2008;168:1718–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Simeon-Aznar CP,
    2. Fonollosa-Pla V,
    3. Tolosa-Vilella C,
    4. Selva-O’Callaghan A,
    5. Solans-Laque R,
    6. Vilardell-Tarres M

    . Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011;30:1393–8.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Koutroumpas A,
    2. Ziogas A,
    3. Alexiou I,
    4. Barouta G,
    5. Sakkas LI

    . Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010;29:1167–8.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Tzouvelekis A,
    2. Galanopoulos N,
    3. Bouros E,
    4. Kolios G,
    5. Zacharis G,
    6. Ntolios P,
    7. et al.

    Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: A meta-analysis. Pulm Med. 2012;2012:143637.

    OpenUrlPubMed
13. 13.↵
    1. Derk CT,
    2. Grace E,
    3. Shenin M,
    4. Naik M,
    5. Schulz S,
    6. Xiong W

    . A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009;48:1595–9.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Herrick AL,
    2. Lunt M,
    3. Whidby N,
    4. Ennis H,
    5. Silman A,
    6. McHugh N,
    7. et al.

    Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010;37:116–24.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Le EN,
    2. Wigley FM,
    3. Shah AA,
    4. Boin F,
    5. Hummers LK

    . Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011;70:1104–7.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Mendoza FA,
    2. Nagle SJ,
    3. Lee JB,
    4. Jimenez SA

    . A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012;39:1241–7.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Yusuf S,
    2. Collins R,
    3. Peto R

    . Why do we need some large, simple randomized trials? Stat Med 1984;3:409–22.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Rovelli F,
    2. De Vita C,
    3. Feruglio GA,
    4. Lotto A,
    5. Selvini A,
    6. Tognoni G

    . GISSI trial: Early results and late follow-up. Gruppo Italiano per la sperimentazione della streptochinasi nell’infarto miocardico. J Am Coll Cardiol 1987;10 Suppl B:33B–39B.

    OpenUrlPubMed
19. 19.↵
    Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) collaborative group. Lancet 1988;2:349–60.

    OpenUrlPubMed
20. 20.↵
    Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989;321:129–35.

    OpenUrlCrossRefPubMed